Cellestia Winner of Venture Leaders China 2018
Cellestia selected as one of the 10 high growth Swiss start-ups composing the new Swiss National Startup Team. The team will fly to China for an exclusive 10-day roadshow for business and investor meetings in September organised by Venture Leaders / swissnex China, including the World Economic Forum Annual Meeting of New Champions in Tianjin
Cancer Care 2018
Oral presentation on CB-103 by Dr. Dirk Weber, Chief Medical Officer, at the “Cancer Care 2018 Innovation & Progress in Switzerland” meeting (Bern, September 14).
Gordon Research Conference
Oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the “Notch, Cancer and Therapeutics” session of the Gordon Research Conference on Notch Signaling in Development, Regeneration and Disease (Lewiston, July 22–27).
European Congress on Biotechnology
Dr. Raj Lehal, Chief Scientific Officer, has given an oral presentation at the European Congress on Biotechnology (Geneva, July 1–4).
8th Conference on NOTCH Targeting in Cancer
Meet the Cellestia team at the 8th Conference on NOTCH Targeting in Cancer (Cyprus, June 20–22).
Clinical Advisory Board
Cellestia strengthens its Clinical Advisory Board by appointing Dr. Carlos L. Arteaga as new member.
Dr. Arteaga is Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, Dallas, Texas. Dr. Arteaga is a world-renown leading figure in the field of breast cancer translational medicine and clinical research, serving in the advisory boards of several academic Breast Cancer Programs and NCI-designated Cancer Centers.
Clinical Advisory Board
Cellestia appoints Dr. Renata Ferrarotto as member of the Clinical Advisory Board.
Dr. Renata Ferrarotto is an Assistant Professor and the Director of the Head and Neck Clinical Research Program at MD Anderson Cancer Center, Houston, Texas. Dr. Ferrarotto is a scientific and clinical expert for head and neck malignancies and her work focuses on the clinical development of novel diagnostic and therapeutic strategies for salivary gland tumors, in particular for adenoid cystic carcinomas.
Strategic Advisory Board
Cellestia appoints David Epstein as Chairman of the Strategic Advisory Board.
First patient dosed in first-in-human Phase l - lla clinical study with CB-103
First dosing of cancer patients in first-in-human Phase l – lla clinical study with CB-103 has started in December 2017.